Adrabetadex - Vtesse/NIH

Drug Profile

Adrabetadex - Vtesse/NIH

Alternative Names: 2-Hydroxypropyl-B-Cyclodextrin; 2-Hydroxypropyl-beta-cyclodextrin; HP-beta-CD; HPBCD; Hydroxypropyl betadex; IT-HPBCD; Kleptose; VTS 270

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer National Institute of Child Health and Human Development; Vtesse; Washington University School of Medicine
  • Class Antidementias; Beta-Cyclodextrins
  • Mechanism of Action Binding agents; Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Niemann-Pick disease type C
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Niemann-Pick disease type C

Most Recent Events

  • 27 Mar 2018 Phase-I/II clinical trials in Niemann-Pick disease type C (In neonates, In infants) in USA (IV)
  • 13 Jun 2017 Sucampo has patent protection for hydroxypropyl betadex in USA
  • 03 Apr 2017 Vtesse has been acquired by Sucampo Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top